yahoo_financeOriginal article
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
Phase 2positiveRademikibartPositive
AI Analysis
Summary
Connect Biopharma announced positive Phase 2 data for Rademikibart in COPD and plans to engage with the FDA regarding its Phase 3 program strategy.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Importance:7/10
Sentiment:
0.70
Phase 2 dataCOPDFDA talksPhase 3 programRademikibart
Related Companies
Read the original article
Published by yahoo_finance on September 30, 2026 2:43 PM